REGENERATE: Obeticholic Acid Improves Liver Fibrosis in Expanded Analysis of Patients With NASH

November 8-12, 2019; Boston, Massachusetts
Obeticholic acid 10 mg and 25 mg improved liver fibrosis, steatohepatitis, and liver biochemistry in expanded ITT population that included patients with fibrosis stages 1-3.
Format: Microsoft PowerPoint (.ppt)
File Size: 169 KB
Released: November 12, 2019

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
AbbVie
Gilead Sciences, Inc.
Intercept Pharmaceuticals, Inc.

Related Content

Expert insight on the burden and impact of HBV infection, as well as strategies to overcome barriers to vaccination, from Clinical Care Options (CCO)

Robert G. Gish, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Released: March 22, 2022 Expired: March 21, 2023

Free slides from CCO featuring data on the prevalence, assessment, and treatment landscape for NASH in people living with HIV.

Jürgen K. Rockstroh, MD Giada Sebastiani, MD Released: February 9, 2022

Expert commentary by Dr Mark S. Sulkowski on the importance of investigating elevated liver enzymes in patients with HIV, from Clinical Care Options (CCO)

Mark S. Sulkowski, MD Released: January 10, 2022

Hear CCO faculty Philip Newsome discuss the agents in late-phase clinical trials and their potential use in treatment of NASH and fibrosis

Philip N. Newsome, PhD, FRCPE Released: February 12, 2020

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings